Biohaven Yönetim

Yönetim kriter kontrolleri 2/4

Biohaven CEO'su Vlad Coric, May2022 tarihinde atandı, in görev süresi 2.5 yıldır. şirketin hisselerinin 3.13% doğrudan sahiptir ve bu hisselerin değeri $ 144.42M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 2.2 yıldır.

Anahtar bilgiler

Vlad Coric

İcra Kurulu Başkanı

US$6.8m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.5yrs
CEO sahipliği	3.1%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	2.2yrs

Son yönetim güncellemeleri

Recent updates

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 18

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Apr 06

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Dec 08

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Dec 04

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Sep 27

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Aug 28

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Jul 22

Biohaven: A Promising Investment In Innovative Neurological Therapies

Jun 14

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Jun 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Apr 06

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

Feb 21

Biohaven Ltd: Assessing The Spinoff

Dec 07

Biohaven Non-GAAP EPS of -$1.25

Nov 09

CEO Tazminat Analizi

Vlad Coric'un ücretlendirmesi Biohaven'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$804m
Jun 30 2024	n/a	n/a	-US$747m
Mar 31 2024	n/a	n/a	-US$517m
Dec 31 2023	US$7m	n/a	-US$408m
Sep 30 2023	n/a	n/a	-US$465m
Jun 30 2023	n/a	n/a	-US$431m
Mar 31 2023	n/a	n/a	-US$544m
Dec 31 2022	US$7m	US$200k	-US$570m

Tazminat ve Piyasa: Vlad 'ın toplam tazminatı ($USD 6.82M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.56M ).

Tazminat ve Kazançlar: Vlad şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Vlad Coric (53 yo)

2.5yrs

Görev süresi

US$6,819,189

Tazminat

Dr. Vladimir Coric, M.D., also known as Vlad, is an Independent Director at Revance Therapeutics, Inc. since March 01, 2023. He is Director at Pyramid Biosciences Inc. since August 2020. He had been Indepe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vladimir Coric	Chairman & CEO	2.5yrs	US$6.82m	3.13% $ 144.4m
Matthew Buten	Chief Financial Officer	no data	US$2.76m	0.19% $ 8.7m
Bruce Car	Chief Scientific Officer	2.3yrs	US$2.58m	0.032% $ 1.5m
Kimberly Gentile	Senior Vice President of Clinical Operations	no data	US$2.56m	0.095% $ 4.4m
Deb Young	Director of Regulatory Affairs & Operations	1.8yrs	Veri yok	Veri yok
George Clark	VP & Chief Accounting Officer	no data	Veri yok	Veri yok
Jennifer Porcelli	Vice President of Investor Relations	no data	Veri yok	Veri yok
Warren Volles	General Counsel & Chief Legal Officer	no data	Veri yok	Veri yok
Clifford Bechtold	President	no data	Veri yok	Veri yok
John Tilton	Chief Commercial Officer of Rare Diseases	no data	Veri yok	Veri yok
Chris Barrett	Senior Vice President of Commercial Strategy	no data	Veri yok	Veri yok
Gilbert L'italien	Senior Vice President of GHEOR & Epidemiology	no data	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: BHVN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Vladimir Coric	Chairman & CEO	2.5yrs	US$6.82m	3.13% $ 144.4m
Douglas Gray	Corporate Secretary & Director	no data	Veri yok	Veri yok
John Childs	Independent Director	2.2yrs	US$555.94k	6.41% $ 295.5m
Julia Gregory	Independent Director	2.2yrs	US$567.94k	0.025% $ 1.2m
Robert Hugin	Independent Director	2.2yrs	US$562.94k	0.013% $ 591.0k
Gregory Bailey	Independent Director	2.2yrs	US$545.94k	1.6% $ 73.9m
Michael Heffernan	Lead Independent Director	2.2yrs	US$597.94k	0.015% $ 692.0k
Richard B. Lipton	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
John Krystal	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Irina Antonijevic	Independent Director	2.2yrs	US$542.94k	0.0025% $ 115.7k
Kishan Mehta	Director	2.2yrs	US$535.94k	0.022% $ 1.0m
Gerard Sanacora	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BHVN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Biohaven Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd., Annual General Meeting, Apr 30, 2024

Recent updates

New major risk - Financial position

Biohaven: A Complicated Tale

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

New minor risk - Share price stability

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Consensus EPS estimates fall by 23%

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $230.000037 million.

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Now 21% overvalued after recent price rise

Biohaven Ltd., Annual General Meeting, Apr 30, 2024

Now 21% overvalued after recent price rise

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

New major risk - Financial position

Director exercised options and sold US$460k worth of stock

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Price target increased by 11% to US$33.17

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Price target increased by 7.8% to US$30.00

Price target increased by 7.4% to US$29.00

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Independent Director recently bought US$402k worth of stock

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Biohaven Ltd. Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Independent Director recently bought US$922k worth of stock

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Independent Director recently bought US$2.0m worth of stock

New minor risk - Share price stability

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

High number of new and inexperienced directors

Biohaven Ltd: Assessing The Spinoff

Biohaven Non-GAAP EPS of -$1.25

Chairman & CEO recently bought US$2.1m worth of stock

Biohaven Ltd. Advances Development of the MoDE Platform Technology Licensed From Yale University

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş